The impact of an antifungal stewardship team on voriconazole therapeutic drug monitoring in a UK tertiary hospital

被引：1
|
作者：
Jones, M. [1 ]
Micallef, C. [1 ,2 ]
Tyler, N. [1 ]
Wong, V. K. [2 ]
Enoch, D. A. [2 ]
机构：
[1] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Pharm Dept, Cambridge, England
[2] Publ Hlth England, Addenbrookes Hosp, Clin Microbiol & Publ Hlth Lab, Natl Infect Serv, Cambridge, England
来源：
JOURNAL OF INFECTION | 2021年 / 83卷 / 03期
关键词：
D O I：
10.1016/j.jinf.2021.07.023
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：E9 / E11
页数：3
相关论文
共 50 条
  • [1] P05 The impact of COVID-19 on antifungal stewardship in a UK tertiary teaching hospital: a review of prescribing practices and therapeutic drug monitoring of posaconazole
    Andreani, Adam
    Tyler, Netta
    Micallef, Christiane
    Enoch, David
    Wong, Vanessa
    JAC-ANTIMICROBIAL RESISTANCE, 2022, 4 (SUPPL 2):
  • [2] Antifungal stewardship in a tertiary hospital
    Ramos, Antonio
    Perez-Velilla, Claudia
    Asensio, Angel
    Ruiz-Antoran, Belen
    Folguera, Carlos
    Cantero, Mireia
    Orden, Beatriz
    Munez, Elena
    REVISTA IBEROAMERICANA DE MICOLOGIA, 2015, 32 (04): : 209 - 213
  • [3] Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital
    Rautemaa-Richardson, R.
    Rautemaa, V.
    Al-Wathiqi, F.
    Moore, C. B.
    Craig, L.
    Felton, T. W.
    Muldoon, E. G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (12) : 3488 - 3495
  • [4] The impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital
    Richardson, R.
    Muldoon, E.
    Richardson, M.
    MYCOSES, 2015, 58 : 150 - 150
  • [5] Promoting antifungal stewardship through an antifungal multidisciplinary team in a paediatric and adult tertiary centre in the UK
    Soni, Shuchita
    Hettle, David
    Hutchings, Stephanie
    Wade, Susan
    Forrest-Jones, Kate
    Sequeiros, Iara
    Borman, Andrew
    Johnson, Elizabeth M.
    Harding, Irasha
    JAC-ANTIMICROBIAL RESISTANCE, 2024, 6 (04):
  • [6] IMPACT OF THERAPEUTIC DRUG MONITORING OF VORICONAZOLE IN A PEDIATRIC POPULATION
    Brueggemann, Roger J. M.
    van der Linden, Jan W. M.
    Verweij, Paul E.
    Burger, David M.
    Warris, Adilia
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (06) : 533 - 534
  • [7] Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital
    Cabral-Galeano, Evelyn
    Ruiz-Camps, Isabel
    Len-Abad, Oscar
    Pou-Clave, Leonor
    Sorde-Masip, Roger
    Meije-Castillo, Yolanda
    Blanco-Grau, Albert
    Barba-Sunol, Pere
    Monforte-Torres, Victor
    Roman-Broto, Antonio
    Pahissa-Berga, Albert
    Gavalda-Santapau, Joan
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2015, 33 (05): : 298 - 302
  • [8] Voriconazole Therapeutic Drug Level Monitoring: A University Hospital Experience
    Kara, Emre
    Ekinci, Pinar Bakir
    Metan, Gokhan
    Ekincioglu, Aygin Bayraktar
    Pinar, Asli
    Akova, Murat
    Uzun, Omrum
    FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, 2022, 27 (01): : 183 - 188
  • [9] Voriconazole therapeutic drug monitoring
    Michael, C.
    Teichert, J.
    Niederwieser, D.
    Preiss, R.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2007, 101 (05) : 367 - 368
  • [10] Therapeutic drug monitoring of voriconazole
    Bruggemann, Roger J. M.
    Donnelly, J. Peter
    Aarnoutse, Rob E.
    Warris, Adilia
    Blijlevens, Nicole M. A.
    Mouton, Johan W.
    Verweij, Paul E.
    Burger, David M.
    THERAPEUTIC DRUG MONITORING, 2008, 30 (04) : 403 - 411
12345